

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NanoLife Holdings LLC	04/24/2008
RECEIVING PARTY DATA	
Name:	NanoLife Sciences, Inc.
Street Address:	351 South Hitchcock Way
City:	Santa Barbara
State/Country:	CALIFORNIA
Postal Code:	93105
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	11690565
CORRESPONDENCE DATA	
Fax Number:	(214)978-3099
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	kalina.k.hulshouser@bakernet.com
Correspondent Name:	Noel C. Gillespie
Address Line 1:	2001 Ross Avenue, Suite 2300
Address Line 2:	Baker & McKenzie LLP
Address Line 4:	Dallas, TEXAS 75201
ATTORNEY DOCKET NUMBER:	67191239.001100
NAME OF SUBMITTER:	Noel C. Gillespie
Total Attachments: 2 source=1100_Assignment#page1.tif source=1100_Assignment#page2.tif	

CH \$40.00 11690565

ASSIGNMENT OF INTELLECTUAL PROPERTY

RECITALS:

NanoLife Holdings, LLC is a Delaware limited liability company, herein called (“Holdings”).

NanoLife Sciences, Inc. is a corporation formed under the laws of Nevada, herein called (“Sciences”).

Sciences is in the business of developing and operating cancer treatment centers using particle therapy.

NanoLife Holdings, LLC is the owner of certain Intellectual Property pertaining to particle treatment of cancer as described in Appendix A, herein called (“IP”).

THEREFORE, BY MUTUAL AGREEMENT:

Holdings hereby transfers all right, title and interest in the IP, without exclusion or reservation of any kind whatsoever, to Sciences for their exclusive use worldwide in the furtherance of their business activities. Such rights include, but are not limited to the selling of both exclusive and non-exclusive licenses either to third parties or Sciences’ partners. Holdings stipulates that the IP being transferred includes any and all interest in any particle therapy related technology for which Holdings has an ownership position.


Holdings hereby acknowledges receipt of good and valuable consideration in exchange for the assignment of the IP to Sciences and the transfer is made in total without any further compensation by Sciences or any of their licensees.

The parties hereby acknowledge that certain of the IP described in Appendix A consists of patents pending, contracts in process, and technology subject to further research and development expense; requiring expenditures to support such ongoing activities. It is agreed that until such time as Sciences obtains financing adequate to cover IP related expenses, Holdings will continue to supply the required funding to pay for IP related expenses and that the consideration already received by Holdings is adequate to cover such expenses.

IN WITNESS WHEREOF, the parties have executed, or have caused their duly authorized representatives to execute, this Agreement as of April 24, 2008.

NanoLife Holdings, LLC

NanoLife Sciences, Inc.



Larry H. Welch, CEO

Ray Winn, President & COO

Appendix A

United States Patent Number : 6,160,263

Container for transporting antiprotons

Page 2

United States Patent Number : 6,14,331

Container for transporting antiprotons and reaction trap

Page 16

United States Patent Number : 6,576,916

Container for transporting antiprotons and reaction trap

Page 35

United States Patent Number : 5,977,554

Container for transporting antiprotons

Page 52

United States Patent Number : US11/690,565

Bi-Polar treatment facility for treating target cells with both positive and negative ions

Page 71

United States Patent Application Number : 20040162457

Antiproton production and delivery for imaging and termination of undesirable cells

Page 74